Literature DB >> 25301422

A generalised sensation of coldness following introduction of rosuvastatin therapy.

Niem Tu Huynh1, Philippe Huot2.   

Abstract

Rosuvastatin is the most potent 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitor commercially available to lower low-density lipoprotein cholesterol. Rosuvastatin has been associated with several adverse effects, including rhabdomyolysis and arthralgias. Here, we report an unusual adverse effect occurring on treatment with rosuvastatin, a 'continuous sensation of coldness'. A 60-year-old man began experiencing this peculiar feeling shortly after introduction of rosuvastatin treatment. The gentleman had to wear extra pair of socks and cover himself with blankets while reading, even during summer with surrounding temperature above 30°C. The abnormal sensation persisted for the 26 months during which he was treated with rosuvastatin, and disappeared within a week after discontinuing treatment. Physical examination, including thorough neurological examination, was entirely normal, as were haematological and biochemical parameters. While the pathophysiology of this phenomenon remains unknown, we hope that this case will encourage others to report similar symptomatology, perhaps enabling to gain more insight on the condition. 2014 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25301422      PMCID: PMC4194946          DOI: 10.1136/bcr-2014-205987

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  14 in total

1.  Rosuvastatin-induced thrombocytopenia.

Authors:  Ioannis Vrettos; Sotiris Papageorgiou; Christina Economopoulou; Vasiliki Pappa; Panagiotis Tsirigotis; Nikolaos Tountas; Theofanis Economopoulos; John Dervenoulas
Journal:  South Med J       Date:  2010-07       Impact factor: 0.954

2.  Dangers of rosuvastatin identified before and after FDA approval.

Authors:  Sidney M Wolfe
Journal:  Lancet       Date:  2004-06-26       Impact factor: 79.321

3.  Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study.

Authors:  Lawrence A Leiter; Robert S Rosenson; Evan Stein; John P D Reckless; Karl-Ludwig Schulte; Margo Schleman; Paul Miller; Michael Palmer; Froukje Sosef
Journal:  Atherosclerosis       Date:  2007-01-16       Impact factor: 5.162

4.  Erythromelalgia accompanying rosuvastatin-associated myopathy.

Authors:  Nevio Cimolai; Tomas Cimolai
Journal:  J Dermatol Case Rep       Date:  2009-04-05

5.  [Rosuvastatin-induced erythema multiforme].

Authors:  Rosmeri Rivera Irigoín; Joana Nicolau Ramis; Fernando Terrasa Sagrista; Lluís Masmiquel Comas
Journal:  Med Clin (Barc)       Date:  2012-12-12       Impact factor: 1.725

6.  Rosuvastatin-induced pemphigoid.

Authors:  Aizuri A Murad; Maureen Connolly; Anne-Marie Tobin
Journal:  BMJ Case Rep       Date:  2012-05-08

7.  Short-term memory loss associated with rosuvastatin.

Authors:  Laura Galatti; Giovanni Polimeni; Francesco Salvo; Marcello Romani; Aurelio Sessa; Edoardo Spina
Journal:  Pharmacotherapy       Date:  2006-08       Impact factor: 4.705

8.  Gynecomastia possibly induced by rosuvastatin.

Authors:  Alessandro Oteri; Maria Antonietta Catania; Rita Travaglini; Alessandra Russo; Saffi E Giustini; Achille P Caputi; Giovanni Polimeni
Journal:  Pharmacotherapy       Date:  2008-04       Impact factor: 4.705

9.  Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program.

Authors:  James Shepherd; Donald G Vidt; Elinor Miller; Susan Harris; James Blasetto
Journal:  Cardiology       Date:  2007-03-16       Impact factor: 1.869

10.  Recurrent acute pancreatitis probably induced by rosuvastatin therapy: a case report.

Authors:  Jayakrishna Chintanaboina; Deepa Gopavaram
Journal:  Case Rep Med       Date:  2012-03-26
View more
  1 in total

1.  Correlations between "hie-sho" interview score and progesterone, fat intake, and Kupperman index in pre- and post-menopausal women: a pilot study.

Authors:  Yuki Uchida; Kyoko Ueshima; Koko Kano; Mayuko Minami; Yuri Mizukami; Keiko Morimoto
Journal:  J Physiol Sci       Date:  2019-05-06       Impact factor: 2.781

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.